Triple negative breast cancer is a particularly malignant and hard to treat type of the disease. At the present there are no established biomarkers and drug targets to aid the diagnosis and prognosis of triple negative breast cancer and to inform rationale- based drug discovery and treatment options. This project will utilize recently developed large-scale post-genomic methods to analyze the proteomes of triple negative breast tumors and establish quantitative protein expression profiles of node- metastatic and non-metastatic tumors. The main objective of the project is to identify and validate proteins which are specifically over expressed in metastatic triple negative breast cancer. Ten metastatic and ten non-metastatic triple negative breast tumors will be profiled at an analytical depth of more than 2,000 proteins. The differentially expressed proteins identified by this large-scale profiling will be validated by immunochemical methods and targeted mass spectrometry assays. The obtained data will provide candidate protein markers and potential drug targets that can be used to develop new, more individualized and more efficient therapies for triple negative breast cancer.

Public Health Relevance

This proposal aims to identify novel protein markers and drug targets for triple negative breast cancer. This form of breast cancer is especially hard to treat as there are no rationale-based therapies available. It has higher incidence in younger pre- menopausal women and women of African and African-American origin. The project will address an urgent need to identify specific markers and drug targets to be used in the development of more efficient and more individualized therapeutic options.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA150131-02
Application #
8209449
Study Section
Special Emphasis Panel (ZCA1-SRLB-F (O1))
Program Officer
Wang, Wendy
Project Start
2011-01-07
Project End
2013-12-31
Budget Start
2012-01-01
Budget End
2013-12-31
Support Year
2
Fiscal Year
2012
Total Cost
$49,300
Indirect Cost
$3,652
Name
University of Essex
Department
Type
DUNS #
424400117
City
Colchester
State
Country
United Kingdom
Zip Code
CO4 3-SQ
Croner, Roland S; St├╝rzl, Michael; Rau, Tilman T et al. (2014) Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis. Int J Cancer 135:2878-86
Metodieva, Gergana; Nogueira-de-Souza, Naiara Correa; Greenwood, Christina et al. (2013) CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia 15:660-8